Author: jeremy

November 17, 2016 – Triphase Accelerator Announces that Celgene Corporation has acquired the company’s assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.

October 4, 2016 – Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.

May 26, 2016 – The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.

January 28, 2016 – Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.

December 16, 2015 – FACIT’s investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.

December 8, 2015 – FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.

November 19, 2015 – Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.